Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEDACNE-2 phase 3 trial of N-Acetyl-GED-0507-34-Levo gel in acne vulgaris
2023-510341-19-00Phase 3Completed
- Sponsor
- PPM Services
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in acne vulgaris comparing N-Acetyl-GED-0507-34-Levo gel 5% with Vehicle control (2 arms). Primary endpoints: Relative change from baseline in total facial lesion count at Week 12 and IGA success at Week 12. Started Sep 2024; status: completed.
02
Drugs
N-acetyl-GED-0507-34-LEVO
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on 2023-510341-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510341-19-00.